Browsing Tag
Palvella Therapeutics
1 post
FDA doubles down on Palvella’s QTORIN rapamycin as Phase 3 SELVA trial exceeds enrollment
Find out how the FDA’s renewed orphan grant is accelerating Palvella Therapeutics’ Phase 3 QTORIN trial toward potential approval in rare disease care.